Skip to main content
Premium Trial:

Request an Annual Quote

Horizon CombinatoRx to Profile Oncology Asset for Pharma Firm

NEW YORK(GenomeWeb) – Horizon Discovery today said that its CombinatoRx division has inked a contract with an unnamed "top 10" pharmaceutical firm to profile a lead oncology asset. 

Horizon CombinatoRx will be paid $750,000 for work completed within a five-month period, it said. The company provides its partners access to the combination high-throughput screening platform and Chalice analytics software for the screening and analysis of thousands of complementary drug combinations. Horizon acquired CombinatoRx in June for $8 million.

Last month, Horizon CombinatoRx announced a similar contract with another undisclosed pharma firm. In July, it signed a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.